Authentic Human Upar/plaur Domain 1 Protein (par-hm1d1) Don't Wait [iFsmzIK9]

Authentic Human Upar/plaur Domain 1 Protein (par-hm1d1) Don't Wait [iFsmzIK9]

The Authentic Human Upar/plaur Domain 1 Protein (par-hm1d1) Don't Wait [iFsmzIK9] is a cutting-edge research tool designed for scientists and researchers in the field of molecular biology and oncology. This protein is derived from human urokinase-type plasminogen activator receptor (uPAR) and its related protein 1 (PLAUR), which play crucial roles in cell adhesion, migration, and invasion. With its high purity and specificity, PAR-HM1D1 is an invaluable asset for various research applications.

Product Properties and Specifications

Our Authentic Human Upar/plaur Domain 1 Protein (par-hm1d1) Don't Wait [iFsmzIK9] is produced through a state-of-the-art expression system, ensuring optimal protein expression and functionality. The protein is isolated from a recombinant source, guaranteeing its purity and consistency. Key specifications include a molecular weight of approximately 30 kDa and a high degree of homology to the native protein. This protein is also biologically active, making it suitable for a range of in vitro assays and experiments.

Practical Uses and Benefits

The Authentic Human Upar/plaur Domain 1 Protein (par-hm1d1) Don't Wait [iFsmzIK9] is a versatile research tool with numerous applications. It is widely used in studies of cancer metastasis, where it helps researchers understand the mechanisms behind cell adhesion and invasion. Additionally, PAR-HM1D1 is valuable for developing novel therapeutic strategies and diagnostic tools. By using this protein, researchers can gain deeper insights into the complex processes of cell signaling and tumor progression. The benefits of using PAR-HM1D1 include:

• Enhanced Research Efficiency: The high purity and activity of PAR-HM1D1 ensure reliable and consistent results, saving time and resources.
• Comprehensive Applications: This protein is suitable for a wide range of experimental setups, from basic research to clinical trials.